{"id":3825,"date":"2018-04-12T08:00:25","date_gmt":"2018-04-12T06:00:25","guid":{"rendered":"https:\/\/ibtherapeutics.com\/sv\/mfn_news\/infant-bacterial-therapeutics-publicerar-arsredovisning-for-2017\/"},"modified":"2023-10-02T13:51:45","modified_gmt":"2023-10-02T11:51:45","slug":"infant-bacterial-therapeutics-publicerar-arsredovisning-for-2017","status":"publish","type":"mfn_news","link":"https:\/\/ibtherapeutics.com\/sv\/pressmeddelanden\/infant-bacterial-therapeutics-publicerar-arsredovisning-for-2017\/","title":{"rendered":"Infant Bacterial Therapeutics publicerar \u00e5rsredovisning f\u00f6r 2017"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/strong><\/div>\n<p>Infant Bacterial Therapeutics AB (publ) publicerar idag \u00e5rsredovisningen f\u00f6r r\u00e4kenskaps\u00e5ret 2017.<br \/>\u00c5rsredovisningen finns tillg\u00e4nglig p\u00e5 IBTs hemsida under avsnittet &#34;Investerare &#8211; Finansiella rapporter&#34; (<a href=\"http:\/\/ibtherapeutics.com\/sv\/investerare\/financial-rapporter\/\" rel=\"nofollow\">http:\/\/ibtherapeutics.com\/sv\/investerare\/financial-rapporter\/<\/a>\u00a0 ).<\/p>\n<p>Aktie\u00e4gare och andra intressenter som \u00f6nskar f\u00e5 \u00e5rsredovisningen skickad till sig kan beg\u00e4ra detta via e-post till IBT@ibtherapeutics.com.<\/p>\n<p><strong><em>Om Infant Bacterial Therapeutics AB<\/em><\/strong><\/p>\n<p>IBT \u00e4r ett mikrobiom l\u00e4kemedelsf\u00f6retag med s\u00e4te i Stockholm vars vision \u00e4r att utveckla l\u00e4kemedel som p\u00e5verkar sp\u00e4dbarns mikrobiom och d\u00e4rigenom kunna f\u00f6rebygga eller behandla s\u00e4llsynta sjukdomar som drabbar f\u00f6r sp\u00e4dbarn.<\/p>\n<p>IBT \u00e4r f\u00f6r n\u00e4rvarande inriktat p\u00e5 att utveckla l\u00e4kemedelskandidaten IBP-9414 f\u00f6r att minska f\u00f6rekomsten av NEC hos f\u00f6r tidigt f\u00f6dda barn. IBP-9414 inneh\u00e5ller Lactobacillus reuteri som aktiv substans, vilket \u00e4r en m\u00e4nsklig bakteriestam som \u00e5terfinns naturligt i br\u00f6stmj\u00f6lk. IBT driver \u00e4ven ett ytterligare projekt, IBP-1016, f\u00f6r behandling av gastroschisis, en allvarlig och s\u00e4llsynt sjukdom som drabbar sp\u00e4dbarn. Genom utvecklingen av dessa l\u00e4kemedel har IBT m\u00f6jlighet att tillfredsst\u00e4lla medicinska behov d\u00e4r det idag inte finns n\u00e5gra tillg\u00e4ngliga behandlingar.<\/p>\n<p>IBT \u00e4r noterat p\u00e5 Nasdaq First North Premier med Erik Penser Bank som Certified Adviser.<\/p>\n<p><strong>F\u00f6r mer information, v\u00e4nligen kontakta<\/strong><br \/>Staffan Str\u00f6mberg, VD<br \/>Infant Bacterial Therapeutics AB<br \/>Bryggargatan 10<br \/>111 21 Stockholm<br \/>Telefon: +46 8 410 145 55<br \/>info@ibtherapeutics.com<br \/><a href=\"http:\/\/www.ibtherapeutics.com\/\" rel=\"nofollow\">www.ibtherapeutics.com<\/a><\/p>\n<p><strong>Offentligg\u00f6rande<\/strong><br \/>Denna information \u00e4r s\u00e5dan information som Infant Bacterial Therapeutics AB \u00e4r skyldigt att offentligg\u00f6ra enligt lagen om v\u00e4rdepappersmarknaden. Informationen l\u00e4mnades f\u00f6r offentligg\u00f6rande den 12 april 2018 kl. 8.00 CET.<\/p>\n<p>   <a href=\"http:\/\/hugin.info\/173361\/R\/2183581\/843512.pdf\" rel=\"nofollow\">PR 20180412 ARSREDOVISNING 2017 SVE<\/a><\/p>\n<p>&#8212;<br \/><em>This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.<br \/>The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.<br \/>Source: Infant Bacterial Therapeutics AB via Globenewswire<\/em><\/p>\n<div class=\"mfn-footer\"><\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment\"><a class=\"mfn-attachment-link\" href=\"https:\/\/storage.mfn.se\/a\/infant-bacterial-therapeutics\/f3df2715-6552-4871-b091-8c606ca6b914\/ibt-arsredovisning-2017.pdf\"><span class=\"mfn-attachment-icon\"><img alt=\"Infant Bacterial Therapeutics publicerar \u00e5rsredovisning f\u00f6r 2017\" src=\"https:\/\/storage.mfn.se\/a\/infant-bacterial-therapeutics\/f3df2715-6552-4871-b091-8c606ca6b914\/ibt-arsredovisning-2017.pdf?type=jpg\"><\/span>IBT \u00c5rsredovisning 2017<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Infant Bacterial Therapeutics AB (publ) publicerar idag \u00e5rsredovisningen f\u00f6r r\u00e4kenskaps\u00e5ret 2017.\u00c5rsredovisningen finns tillg\u00e4nglig p\u00e5 IBTs hemsida under avsnittet &#34;Investerare &#8211; Finansiella rapporter&#34; (http:\/\/ibtherapeutics.com\/sv\/investerare\/financial-rapporter\/\u00a0 ). Aktie\u00e4gare och andra intressenter som \u00f6nskar f\u00e5 \u00e5rsredovisningen skickad till sig kan beg\u00e4ra detta via e-post till IBT@ibtherapeutics.com. Om Infant Bacterial Therapeutics AB IBT \u00e4r ett mikrobiom l\u00e4kemedelsf\u00f6retag med s\u00e4te i [&hellip;]<\/p>\n","protected":false},"template":"","_links":{"self":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3825"}],"collection":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=3825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}